NASDAQ:MNKDMannKind Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.60 +0.01 (+0.63 %) (As of 08/12/2020 04:00 PM ET) Add Compare Share Today's Range$1.57Now: $1.60▼$1.6550-Day Range$1.56MA: $1.70▼$2.1352-Week Range$0.80Now: $1.60▼$2.48Volume1.94 million shsAverage Volume3.06 million shsMarket Capitalization$366.68 millionP/E RatioN/ADividend YieldN/ABeta2.2 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company has a licensing and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingMannKind has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, MannKind has a potential upside of 87.5% from its current price of $1.60.Amount of Analyst CoverageMannKind has only been the subject of 2 research reports in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesMannKind has received 545 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMannKind has received 719 “underperform” votes. (Add your “underperform” vote.)Community SentimentMannKind has received 56.88% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about MannKind and other stocks. Vote “Outperform” if you believe MNKD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MNKD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMannKind does not currently pay a dividend.Dividend GrowthMannKind does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MannKind insiders have bought more of their company's stock than they have sold. Specifically, they have bought $52,948.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.09% of the stock of MannKind is held by insiders.Percentage Held by InstitutionsOnly 24.41% of the stock of MannKind is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MannKind are expected to grow in the coming year, from ($0.19) to ($0.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MannKind is -7.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MannKind is -7.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.87 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MNKD Previous Symbol CUSIP56400P20 CIK899460 Webwww.mannkindcorp.com Phone818-661-5000Debt Debt-to-Equity RatioN/A Current Ratio1.07 Quick Ratio1.01Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$63.04 million Price / Sales5.82 Cash FlowN/A Price / Cash FlowN/A Book Value($0.92) per share Price / Book-1.74Profitability EPS (Most Recent Fiscal Year)($0.27) Net Income$-51,900,000.00 Net Margins-71.37% Return on EquityN/A Return on Assets-45.92%Miscellaneous Employees225 Outstanding Shares229,175,000Market Cap$366.68 million Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $1.60 +0.01 (+0.63 %) (As of 08/12/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MNKD News and Ratings via Email Sign-up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. MannKind (NASDAQ:MNKD) Frequently Asked Questions How has MannKind's stock price been impacted by COVID-19? MannKind's stock was trading at $1.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MNKD shares have increased by 45.5% and is now trading at $1.60. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of MannKind? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MannKind. When is MannKind's next earnings date? MannKind is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for MannKind. How were MannKind's earnings last quarter? MannKind Co. (NASDAQ:MNKD) issued its earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.05) by $0.00. The biopharmaceutical company earned $15.11 million during the quarter, compared to analyst estimates of $15.19 million. View MannKind's earnings history. What price target have analysts set for MNKD? 5 equities research analysts have issued 12-month price targets for MannKind's stock. Their forecasts range from $2.50 to $4.00. On average, they anticipate MannKind's stock price to reach $3.00 in the next year. This suggests a possible upside of 87.5% from the stock's current price. View analysts' price targets for MannKind. Has MannKind been receiving favorable news coverage? News headlines about MNKD stock have been trending extremely negative this week, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. MannKind earned a media sentiment score of -4.1 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news about MannKind. Who are some of MannKind's key competitors? Some companies that are related to MannKind include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX). View all competitors. What other stocks do shareholders of MannKind own? Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Novavax (NVAX), ACADIA Pharmaceuticals (ACAD), Geron (GERN), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU) and NVIDIA (NVDA). Who are MannKind's key executives? MannKind's management team includes the following people: Dr. Michael E. Castagna, CEO & Director (Age 42)Mr. Steven B. Binder, Chief Financial Officer (Age 56)Mr. Joseph Kocinsky, Chief Technology Officer (Age 55)Ms. Rosabel Realica Alinaya, Sr. VP of Investor Relations & Treasury (Age 58)Dr. David B. Thomson, Corp. VP, Gen. Counsel & Sec. (Age 52) What is MannKind's stock symbol? MannKind trades on the NASDAQ under the ticker symbol "MNKD." Who are MannKind's major shareholders? MannKind's stock is owned by a variety of retail and institutional investors. Top institutional investors include Emerald Advisers LLC (0.83%), Emerald Mutual Fund Advisers Trust (0.75%), Bank of New York Mellon Corp (0.29%), Dupont Capital Management Corp (0.31%), 180 Wealth Advisors LLC (0.22%) and California Public Employees Retirement System (0.21%). Company insiders that own MannKind stock include Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder and Stuart A Tross. View institutional ownership trends for MannKind. Which major investors are buying MannKind stock? MNKD stock was purchased by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, California Public Employees Retirement System, Bank of New York Mellon Corp, New York State Common Retirement Fund, SG Americas Securities LLC, 180 Wealth Advisors LLC, and Beirne Wealth Consulting Services LLC. Company insiders that have bought MannKind stock in the last two years include Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder, and Stuart A Tross. View insider buying and selling activity for MannKind. How do I buy shares of MannKind? Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is MannKind's stock price today? One share of MNKD stock can currently be purchased for approximately $1.60. How big of a company is MannKind? MannKind has a market capitalization of $366.68 million and generates $63.04 million in revenue each year. The biopharmaceutical company earns $-51,900,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. MannKind employs 225 workers across the globe. What is MannKind's official website? The official website for MannKind is www.mannkindcorp.com. How can I contact MannKind? MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected] This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
